Device/Diagnostics Quarterly Dealmaking Statistics, Q1 2019
A look at the financing, M&A and alliance activity in January–March 2019
Device financing totaled $1.6bn for the first quarter of 2019. Late-stage venture rounds were the most active category, led by Nuvaira's $79m Series E financing. Merger and acquisition activity reached $7.3bn; in the largest transaction of the quarter, Ethicon acquired Auris Health for up to $6bn. Diagnostics/research financing reached $1.7bn, and ten diagnostics/research tools companies were acquired, five of which together were valued at $22.6bn.
You may also be interested in...
Oncimmune Expands Application Of Liquid Biopsy Auto-Antibody Technology
The company’s liquid biopsy test business is complemented by a patient-stratification service for pharmaceutical companies.
Inivata Raises $52.6M For Liquid Biopsy Commercialization
Inivata has raised $52.6m to support commercialization of its blood test for non-small cell lung cancer (NSCLC) diagnosis.
Market Intel: Liquid Biopsy – Ready For Prime Time?
Liquid biopsy is a rapidly developing noninvasive technology for the early detection of cancer. Multiple companies have entered clinical testing, using mostly blood to detect circulating tumor cells and/or circulating tumor DNA. But urine and even cerebral spinal fluid are promising liquids too. Regardless of the fluid, testing costs a fraction of a traditional, invasive tissue biopsy and offers much quicker results.